Literature DB >> 26401591

Aldosterone Impairs Vascular Smooth Muscle Function: From Clinical to Bench Research.

Chia-Hung Chou1, Ying-Hsien Chen1, Chi-Sheng Hung1, Yi-Yao Chang1, Yu-Lin Tzeng1, Xue-Ming Wu1, Vin-Cent Wu1, Chia-Ti Tsai1, Cho-Kai Wu1, Yi-Lwun Ho1, Kwan-Dun Wu1, Yen-Hung Lin1.   

Abstract

CONTEXT: The effect of aldosterone on vascular smooth muscle cell function is still unclear. One method to measure vascular smooth muscle cell function is endothelial-independent vascular dilation, for which the key factor is sarcoplasmic reticulum calcium adenosine triphosphatase (SERCA).
OBJECTIVE: Our objective was to investigate the effect of aldosterone on vascular smooth muscle cell function and SERCA regulation.
DESIGN: We prospectively analyzed 35 patients with primary aldosteronism (PA; 32 patients with aldosterone-producing adenoma and three patients with idiopathic hyperaldosteronism) and 30 patients with essential hypertension (EH) who were enrolled as the control group. Flow and nitrate-mediated dilation were performed in both groups and 1 year after adrenalectomy in the patients with aldosterone-producing adenoma. In addition, we investigated the effect of aldosterone on SERCA regulation in human aortic smooth muscle cells.
SETTING: This study took place in an academic clinical research center. PARTICIPANTS: Participants included 35 patients with PA and 30 patients with EH.
INTERVENTIONS: Adrenalectomy was undertaken in patients with aldosterone-producing adenoma.
RESULTS: The PA patients had significantly lower flow-mediated dilation (FMD) and nitrate-mediated dilation (NMD) values than the patients with EH (FMD: 13 ± 6 vs 16 ± 4; NMD: 16 ± 6 vs 19 ± 5; both P < .05). FMD/NMD were significantly correlated with log 24 hour-urine aldosterone (FMD: r = -0.287, P = .048; NMD: r = -0.402, P = .005) but not blood pressure. The impaired FMD and NMD values were significantly restored 1 year after adrenalectomy (FMD: 11 ± 4 to 19 ± 7; NMD: 15 ± 6 to 21 ± 6; both P < .01). Under confocal microscopy, aldosterone was shown to suppress the expression of SERCA2a of human aortic smooth muscle cells. Aldosterone significantly suppressed the expression of SERCA2a from 10(-8) M in mRNA and protein levels. This suppression was through down-regulation of mineralocorticoid receptor dependent mitochondrial transcription factors A and B2.
CONCLUSIONS: Aldosterone impairs vascular smooth muscle cell function and suppresses SERCA 2a expression.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26401591     DOI: 10.1210/jc.2015-2752

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  16 in total

Review 1.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

2.  Dual benefits of renin-angiotensin-aldosterone blockade: lowering the blood pressure and de-stiffening the arteries.

Authors:  Chun-Yih Hsieh; Yen-Hung Lin
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Arterial stiffness and blood pressure improvement in aldosterone-producing adenoma harboring KCNJ5 mutations after adrenalectomy.

Authors:  Chia-Hui Chang; Ya-Hui Hu; Yao-Chou Tsai; Che-Hsiung Wu; Shuo-Meng Wang; Lian-Yu Lin; Yen-Hung Lin; Fumitoshi Satoh; Kwan-Dun Wu; Vin-Cent Wu
Journal:  Oncotarget       Date:  2017-05-02

4.  Edaravone inhibits pressure overload-induced cardiac fibrosis and dysfunction by reducing expression of angiotensin II AT1 receptor.

Authors:  Wei-Wei Zhang; Feng Bai; Jin Wang; Rong-Hua Zheng; Li-Wang Yang; Erskine A James; Zhi-Qing Zhao
Journal:  Drug Des Devel Ther       Date:  2017-10-16       Impact factor: 4.162

5.  Surgical outcomes of patients with primary aldosteronism lateralized with I-131-6 β-iodomethyl-norcholesterol single photon emission/computed tomography without discontinuation or modification of antihypertensive medications.

Authors:  Chia-Hui Chang; Stephen Shei-Dei Yang; Yao-Chou Tsai; Shi-Wen Kuo; Shiou-Chi Cherng; Ching-Chu Lu; Ruoh-Fang Yen; Vin-Cent Wu; Ya-Hui Hu
Journal:  Ci Ji Yi Xue Za Zhi       Date:  2018 Jul-Sep

6.  Aldosteronism with mild hypokalemia presenting as life-threatening ventricular arrhythmias: A case report.

Authors:  Dongpu Shao; Shudong Wang; Shanshan Zhou; Qingyuan Cai; Rangrang Zhang; Hang Li; Yang Zheng; Zhiguo Zhang
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

7.  Comparison of biomarkers of endothelial dysfunction and microvascular endothelial function in patients with primary aldosteronism and essential hypertension.

Authors:  Miaomiao Sang; Yu Fu; Chenmin Wei; Jing Yang; Xueting Qiu; Jingqing Ma; Chao Qin; Feiyan Wu; Xueling Zhou; Tao Yang; Min Sun
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2021 Jan-Dec       Impact factor: 1.636

8.  Time course and factors predicting arterial stiffness reversal in patients with aldosterone-producing adenoma after adrenalectomy: prospective study of 102 patients.

Authors:  Che-Wei Liao; Lian-Yu Lin; Chi-Sheng Hung; Yen-Tin Lin; Yi-Yao Chang; Shuo-Meng Wang; Vin-Cent Wu; Kwan-Dun Wu; Yi-Lwun Ho; Fumitoshi Satoh; Yen-Hung Lin
Journal:  Sci Rep       Date:  2016-02-17       Impact factor: 4.379

Review 9.  Thoracic Aortic Aneurysm Development in Patients with Bicuspid Aortic Valve: What Is the Role of Endothelial Cells?

Authors:  Vera van de Pol; Kondababu Kurakula; Marco C DeRuiter; Marie-José Goumans
Journal:  Front Physiol       Date:  2017-11-30       Impact factor: 4.566

10.  Hyperaldosteronism and cardiovascular risk in patients with autosomal dominant polycystic kidney disease.

Authors:  Silvia Lai; Luigi Petramala; Daniela Mastroluca; Emanuela Petraglia; Alessandro Di Gaeta; Elena Indino; Valeria Panebianco; Mauro Ciccariello; Hossein H Shahabadi; Alessandro Galani; Claudio Letizia; Anna Rita D'Angelo
Journal:  Medicine (Baltimore)       Date:  2016-07       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.